miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common hepatic disease with an increasing prevalence but an unclear aetiology. This study aimed to investigate the functional implications of microRNA-122 (miR-122) in the pathogenesis of NAFLD and the possible molecular mechanisms. METHODS: Both in vitro and in vivo models of NAFLD were generated by treating HepG2 and Huh-7 cells with free fatty acids (FFA) and by feeding mice a high-fat diet (HFD), respectively. HE and Oil Red O staining were used to examine liver tissue morphology and lipid deposition, respectively. Immunohistochemical (IHC) staining was used to examine Sirt1 expression in liver tissues. qRT-PCR and Western blotting were employed to measure the expression of miR-122, Sirt1, and proteins involved in lipogenesis and the AMPK pathway. Enzyme-linked immunosorbent assay (ELISA) was used to quantify triglyceride (TG) levels in HepG2 and Huh-7 cells and in liver tissues. The interaction between miR-122 and the Sirt1 gene was further examined by a dual luciferase reporter assay and RNA-immunoprecipitation (RIP). RESULTS: NAFLD hepatic tissues and FFA-treated HepG2 and Huh-7 cells presented excess lipid production and TG secretion, accompanied by miR-122 upregulation, Sirt1 downregulation, and potentiated lipogenesis-related genes. miR-122 suppressed Sirt1 expression via binding to its 3'-untranslated region (UTR). Knockdown of miR-122 effectively mitigated excessive lipid production and suppressed the expression of lipogenic genes in FFA-treated HepG2 and Huh-7 cells via upregulating Sirt1. Furthermore, miR-122 knockdown activated the LKB1/AMPK signalling pathway. CONCLUSION: The inhibition of miR-122 protects hepatocytes from lipid metabolic disorders such as NAFLD and suppresses lipogenesis via elevating Sirt1 and activating the AMPK pathway. These data support miR-122 as a promising biomarker and drug target for NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs reduce liver fat accumulation by activating AMPK, which inhibits fatty acid synthesis enzymes and promotes fatty acid β-oxidation, thus diminishing lipid droplet accumulation in hepatocytes.508–511”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [509]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300
MicroRNAs in metabolism and metabolic disorders
Rottiers, V., & Näär, A. M. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3313 · Cited by 1,156
Purushotham, A., Schug, T. T., Xu, Q., Surapureddi, S., Guo, X., & Li, X. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.02.006 · Cited by 1,003
SIRT1 Modulation of the Acetylation Status, Cytosolic Localization, and Activity of LKB1
Lan, F., Cacicedo, J. M., Ruderman, N., & Ido, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805711200 · Cited by 825
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer
Herranz, D., Muñoz-Martin, M., Cañamero, M., Mulero, F., Martinez-Pastor, B., Fernandez-Capetillo, O., & Serrano, M. (2010) · Nature Communications · doi:10.1038/ncomms1001 · Cited by 612
Pirola, C. J., Fernández Gianotti, T., Castaño, G. O., Mallardi, P., San Martino, J., Mora Gonzalez Lopez Ledesma, M., Flichman, D., Mirshahi, F., Sanyal, A. J., & Sookoian, S. (2015) · Gut · doi:10.1136/gutjnl-2014-306996 · Cited by 564
Li, X. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms108 · Cited by 360 · cited 1×
“Sirt1 also modulates the expression of various genes involved in glucose and lipid metabolism (Li, 2013).”
BackgroundCastro, R. E., Ferreira, D. M. S., Afonso, M. B., Borralho, P. M., Machado, M. V., Cortez-Pinto, H., & Rodrigues, C. M. P. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.08.008 · Cited by 350
Lin, R., Elf, S., Shan, C., Kang, H.-B., Ji, Q., Zhou, L., Hitosugi, T., Zhang, L., Zhang, S., Seo, J. H., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3255 · Cited by 287
Spengler, E. K., & Loomba, R. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.06.013 · Cited by 284
Dai, W., Ye, L., Liu, A., Wen, S. W., Deng, J., Wu, X., & Lai, Z. (2017) · Medicine · doi:10.1097/md.0000000000008179 · Cited by 268
Self-citationSirt1 Activation Ameliorates Renal Fibrosis by Inhibiting the TGF‐β/Smad3 Pathway
Huang, X., Wen, D., Zhang, M., Xie, Q., Ma, L., Guan, Y., Ren, Y., Chen, J., & Hao, C. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24748 · Cited by 200
The expression of SIRT1 in nonalcoholic fatty liver disease induced by high‐fat diet in rats
Deng, X., Chen, L., & Li, N. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01497.x · Cited by 175
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Takahashi, Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i13.3777 · Cited by 161
Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia
Ng, R., Wu, H., Xiao, H., Chen, X., Willenbring, H., Steer, C. J., & Song, G. (2014) · Hepatology · doi:10.1002/hep.27153 · Cited by 154
Miyaaki, H., Ichikawa, T., Kamo, Y., Taura, N., Honda, T., Shibata, H., Milazzo, M., Fornari, F., Gramantieri, L., Bolondi, L., et al. (2014) · Liver International · doi:10.1111/liv.12429 · Cited by 147
Sirtuins and nonalcoholic fatty liver disease
Nassir, F., & Ibdah, J. A. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i46.10084 · Cited by 135
Latorre, J., Moreno‐Navarrete, J. M., Mercader, J. M., Sabater, M., Rovira, O., Gironès, J., Ricart, W., Fernández‐Real, J. M., & Ortega, F. J. (2017) · International Journal of Obesity · doi:10.1038/ijo.2017.21 · Cited by 131
da Silva-Santi, L. G., Antunes, M. M., Caparroz‐Assef, S. M., Carbonera, F., Masi, L. N., Curi, R., Visentainer, J. V., & Bazotte, R. B. (2016) · Nutrients · doi:10.3390/nu8110682 · Cited by 129
Serum miR-29a and miR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD)
Jampoka, K., Muangpaisarn, P., Khongnomnan, K., Treeprasertsuk, S., Tangkijvanich, P., & Payungporn, S. (2018) · MicroRNA · doi:10.2174/2211536607666180531093302 · Cited by 125
Wang, L.-F., Wang, X.-N., Huang, C.-C., Hu, L., Xiao, Y.-F., Guan, X.-H., Qian, Y.-S., Deng, K.-Y., & Xin, H.-B. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0464-z · Cited by 124
Sun, L., Wang, Y., Song, Y., Cheng, X., Xia, S., Rahman, M. R. T., Shi, Y., & Le, G. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.072 · Cited by 117
Santamarina, A. B., de Oliveira, J. L., da Silva, F. P., Carnier, J., Mennitti, L. V., de Santana, A. A., Gabriel, H. I. D. S., Ribeiro, E. B., do Nascimento, C. M. O., Lira, F. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141227 · Cited by 114
Dai, H., Wang, W., Chen, R., Chen, Z., Lu, Y., & Yuan, H. (2017) · Nutrition & Metabolism · doi:10.1186/s12986-017-0206-2 · Cited by 113
Chen, X., Zhao, M., Huang, J., Li, Y., Wang, S., Harrington, C. A., Qian, D. Z., Sun, X., & Dai, M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26739 · Cited by 105
A Potential Treatment of Non-Alcoholic Fatty Liver Disease with SIRT1 Activators
Çolak, Y., Yeşıl, A., Mutlu, H. H., Çaklılı, Ö. T., Ulaşoğlu, C., Şenateş, E., Takır, M., Köstek, O., Yilmaz, Y. N., Enc, F. Y., et al. (2014) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.233.yck · Cited by 102
Ye, D., Zhang, T., Lou, G., Xu, W., Dong, F., Chen, G., & Liu, Y. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.07.029 · Cited by 95
Kim, H. J., Joe, Y., Yu, J. K., Chen, Y., Jeong, S. O., Mani, N., Cho, G. J., Pae, H., Ryter, S. W., & Chung, H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.04.017 · Cited by 94
Li, J., Li, W., Li, J., Li, Y., Song, H., Luan, Y., Qi, H., Ma, L., Lü, X., & Yang, Y. (2016) · Scientific Reports · doi:10.1038/srep36209 · Cited by 91
Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease
Yamada, H., Ohashi, K., Suzuki, K. A. O., Munetsuna, E., Ando, Y., Yamazaki, M., Ishikawa, H., Ichino, N., Teradaira, R., & Hashimoto, S. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.05.002 · Cited by 86
Alizadeh, E., Akbarzadeh, A., Eslaminejad, M. B., Barzegar, A., Hashemzadeh, S., Nejati‐Koshki, K., & Zarghami, N. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12398 · Cited by 78
Dual Role of MicroRNAs in NAFLD
Ceccarelli, S., Panera, N., Gnani, D., & Nobili, V. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14048437 · Cited by 67
Sendi, H., Mead, I., Wan, M., Mehrab-Mohseni, M., Koch, K., Atala, A., Bonkovsky, H. L., & Bishop, C. E. (2018) · PLOS ONE · doi:10.1371/journal.pone.0200847 · Cited by 66
MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1
Wu, G., Rui, C., Chen, J.-Q., Sho, E., Zhan, S., Yuan, X., & Ding, Y.-T. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485765 · Cited by 62
MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease
Panera, N. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15079 · Cited by 60
Differential TGFβ pathway targeting by miR-122 in humans and mice affects liver cancer metastasis
Yin, S., Fan, Y., Zhang, H., Zhao, Z., Hao, Y., Li, J., Sun, C., Yang, J., Yang, Z., Yang, X., et al. (2016) · Nature Communications · doi:10.1038/ncomms11012 · Cited by 59
Li, X., Lian, F., Liu, C., Hu, K., & Wang, X. (2015) · Scientific Reports · doi:10.1038/srep16774 · Cited by 57
Braza‐Boïls, A., Marí‐Alexandre, J., Molina, P., Arnau, M. Á., Barceló‐Molina, M., Domingo, D., Girbés, J., Giner, J., Martínez‐Dolz, L., & Zorio, E. (2016) · Liver International · doi:10.1111/liv.13097 · Cited by 53
Akuta, N., Kawamura, Y., Suzuki, F., Saitoh, S., Arase, Y., Fujiyama, S., Sezaki, H., Hosaka, T., Kobayashi, M., Suzuki, Y., et al. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0557-6 · Cited by 49
Circulating levels of miR‐122 and nonalcoholic fatty liver disease in pre‐pubertal obese children
Brandt, S., Roos, J., Inzaghi, E., Kotnik, P., Kovač, J., Battelino, T., Cianfarani, S., Nobili, V., Colajacomo, M., Kratzer, W., et al. (2017) · Pediatric Obesity · doi:10.1111/ijpo.12261 · Cited by 48
Lin, M., Dai, W., Scott, M. J., Li, R., Zhang, Y.-Q., Yang, Y., Chen, L.-Z., & Huang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.22163 · Cited by 34
Self-citationLKB1 signalling attenuates early events of adipogenesis and responds to adipogenic cues
Gormand, A., Berggreen, C., Amar, L., Henriksson, E., Lund, I., Albinsson, S., & Göransson, O. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0296 · Cited by 32
Ao, R., Wang, Y., Tong, J., & Wang, B. (2016) · Medical Science Monitor · doi:10.12659/msm.897207 · Cited by 31
Xinnan, H., Zhang, J., Jiang, Y., Lei, Y., Lu, L., Zhou, J. F., Huang, H., Fang, D., & Tao, G. (2014) · Toxicology in Vitro · doi:10.1016/j.tiv.2014.07.004 · Cited by 25
Chen, L., Deng, X., & Li, N. (2007) · PubMed · Cited by 24
Chu, M. J. J., Hickey, A. J., Tagaloa, S., Zhang, L., Dare, A. J., MacDonald, J. R., Yeong, M., Bartlett, A. S. J. R., & Phillips, A. R. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100609 · Cited by 18
Silva, A. K. S. E., Torres, D. D. O. C., Gomes, F. O. D. S., Silva, B. D. S., Ribeiro, E. L., Oliveira, A. C., dos Santos, L. A. M., de Lima, M. D. C. A., Pitta, I. D. R., & Peixoto, C. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123787 · Cited by 17
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study
Wu, Y.-L., Lin, Z.-J., Li, C.-C., Lin, X., Shan, S.-K., Guo, B., Zheng, M.-H., Li, F., Yuan, L.-Q., & Li, Z.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01333-7 · Cited by 476
“miR-122 aggravates hepatic lipogenesis by targeting SIRT1 and activating the LKB1-AMPK cascade.(246) Lee et al.”
BackgroundNAFLD: Mechanisms, Treatments, and Biomarkers
Nassir, F. (2022) · Biomolecules · doi:10.3390/biom12060824 · Cited by 405
The AMPK pathway in fatty liver disease
Fang, C., Pan, J., Qu, N., Lei, Y., Han, J., Zhang, J., & Han, D. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.970292 · Cited by 364
“(2009) found that AMPK was located upstream of Sirt1 and could increase Sirt1 activity by increasing the intracellular AMP/ATP ratio, particularly the level of NAD/NADH (Long et al., 2019).”
BackgroundMechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review
Rinaldi, L., Pafundi, P. C., Galiero, R., Caturano, A., Morone, M. V., Silvestri, C., Giordano, M., Salvatore, T., & Sasso, F. C. (2021) · Antioxidants · doi:10.3390/antiox10020270 · Cited by 171
“In particular, miR-122 appears upregulated in the presence of a high-fat diet, thus resulting in the promotion of lipogenesis in the liver [162].”
Background
Metadata
- Authors
- Long, J.-K., Dai, W., Zheng, Y.-W., & Zhao, S.-P.
- Affiliations
- Second Xiangya Hospital of Central South University (CN)
- Corresponding author
- Zhao, Shui-Ping
- Venue
- Molecular Medicine
- Published
- 2019-06-13
- Volume
- 25
- Issue
- 1
- Pages
- 26-26
- ISSN
- 1076-1551 (ISSN-L)
- 1528-3658
- PMC
- PMC6567918
- OpenAlex
- W2952409891
- Cited by
- 281
- References
- 48
- Citations by year
- 2026: 36 · 2025: 53 · 2024: 52 · 2023: 57 · 2022: 48 · 2021: 21 · 2020: 13 · 2019: 1
- FWCI
- 15.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- miR-122, non-alcoholic fatty liver disease, hepatic lipogenesis, SIRT1, LKB1/AMPK pathway, microRNA, free fatty acids, triglyceride secretion, 3' untranslated region, lipid metabolism, hepatocytes, high-fat diet, biomarkers, therapeutic target
- MeSH terms
- Enzyme-Linked Immunosorbent Assay, Humans, Immunohistochemistry, Liver, Signal Transduction, MicroRNAs, Cell Line, Tumor, Lipogenesis, Lipid Metabolism, AMP-Activated Protein Kinases, Sirtuin 1, Hep G2 Cells, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.